stockrow
Friday 6 November 2026
Export SRPT’s income statement to Excel — free account
Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
17.71
0.14
+0.80%
Follow SRPT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 29.81 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.99 | 0.96 | 1.05 | 0.98 | |
P/FCF ratio |
11.39 | 25.27 | 21.11 | 0.00 | |
P/Operating CF |
32.19 | 9.61 | (11.27) | 16.42 | |
P/B ratio |
1.26 | 1.24 | 1.52 | 1.89 | |
Price to Tangible BV |
1.27 | 1.25 | 1.53 | 1.91 | |
EV/Sales |
0.98 | 1.04 | 1.17 | 0.97 | |
EV/EBITDA |
0.00 | 0.00 | 9,628.22 | 0.00 | |
EV/Operating CF |
10.29 | 18.43 | 14.61 | (10.39) | |
EV/FCF |
11.26 | 27.28 | 23.66 | (6.77) | |
Quick Ratio |
1.90 | 2.32 | 2.10 | 1.22 | |
Current Ratio |
3.46 | 4.42 | 4.63 | 2.32 | |
Net Debt/EBITDA |
0.00 | 2.59 | 0.50 | 0.27 | |
Debt/Assets |
27.08% | 26.58% | 26.37% | 24.75% | |
Debt/Equity |
0.56 | 0.55 | 0.56 | 0.73 | |
Asset Turnover |
0.59 | 0.57 | 0.66 | 0.60 | |
Operating CF/Net income |
(2.11) | (40.30) | (0.61) | (0.32) | |
Capex/Depreciation |
0.00 | (0.06) | (0.31) | (0.77) | |
Research and Development Expense of Revenue |
21.65% | 22.74% | 21.07% | 73.45% | |
Selling, General and Administrative Expense of Revenue |
31.10% | 26.82% | 14.91% | 28.97% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.01% | 6.10% | 4.02% | 6.78% | |
Graham Net Nets |
0.33 | 0.30 | 0.28 | 0.15 | |
Graham Number |
0.00 | 0.00 | 15.35 | 0.00 | |
Earnings Yield |
(6.04%) | (7.40%) | 3.35% | (32.62%) | |
Free Cash Flow Yield |
8.78% | 3.96% | 4.74% | (14.64%) | |
Revenue per Share |
3.60 | 3.81 | 6.96 | 4.42 | |
Operating CF per Share |
0.57 | 1.87 | (1.93) | 1.31 | |
Capex per Share |
(0.03) | (0.01) | (0.03) | (0.04) | |
Free Cash Flow per Share |
0.54 | 1.86 | (1.96) | 1.27 | |
Cash per Share |
8.30 | 7.48 | 6.22 | 9.39 | |
Shareholders Equity per Share |
14.43 | 14.49 | 14.34 | 11.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.43 | 14.49 | 14.34 | 11.39 | |
Free Cash Flow |
57.03 | 196.52 | (205.76) | 127.48 | |
Working Capital |
1,616.54 | 1,720.92 | 1,810.71 | 1,442.65 | |
Capital Expenditures |
(2.93) | (0.55) | (3.08) | (3.73) | |
Net Current Asset Value |
635.68 | 563.11 | 636.04 | 328.86 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
382.46 | 452.06 | 527.09 | 500.11 | |
Average Payables |
69.86 | 93.84 | 113.24 | 247.64 | |
Average Inventory |
976.64 | 949.15 | 971.27 | 832.35 | |
Average Assets |
3,329.75 | 3,434.16 | 3,322.16 | 3,656.44 | |
Average Common Equity |
1,424.49 | 1,442.59 | 1,323.91 | 1,334.18 |
Columns are period end dates · fundamentals updated 5 Nov 2026